AP2000001735A0 - Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. - Google Patents

Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.

Info

Publication number
AP2000001735A0
AP2000001735A0 APAP/P/2000/001735A AP2000001735A AP2000001735A0 AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0 AP 2000001735 A AP2000001735 A AP 2000001735A AP 2000001735 A0 AP2000001735 A0 AP 2000001735A0
Authority
AP
ARIPO
Prior art keywords
treatment
alpha
diabetes
glucocidase
inhibitor
Prior art date
Application number
APAP/P/2000/001735A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP2000001735A0 publication Critical patent/AP2000001735A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
APAP/P/2000/001735A 1997-07-18 2000-01-14 Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. AP2000001735A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (fr) 1997-07-18 1998-07-16 Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase

Publications (1)

Publication Number Publication Date
AP2000001735A0 true AP2000001735A0 (en) 2000-01-16

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001735A AP2000001735A0 (en) 1997-07-18 2000-01-14 Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.

Country Status (27)

Country Link
EP (1) EP1001784A1 (fr)
JP (1) JP2001510160A (fr)
KR (1) KR20010021952A (fr)
CN (1) CN1263467A (fr)
AP (1) AP2000001735A0 (fr)
AR (2) AR016350A1 (fr)
AU (1) AU8449098A (fr)
BG (1) BG104062A (fr)
BR (1) BR9810292A (fr)
CA (1) CA2297133A1 (fr)
CO (1) CO4940489A1 (fr)
DZ (1) DZ2563A1 (fr)
EA (1) EA200000140A1 (fr)
GB (1) GB9715298D0 (fr)
HU (1) HUP0003626A3 (fr)
ID (1) ID23804A (fr)
IL (1) IL133907A0 (fr)
MA (1) MA24608A1 (fr)
NO (1) NO20000230L (fr)
OA (1) OA11312A (fr)
PE (1) PE99499A1 (fr)
PL (1) PL338140A1 (fr)
SK (1) SK612000A3 (fr)
TR (1) TR200000133T2 (fr)
UY (1) UY25101A1 (fr)
WO (1) WO1999003478A1 (fr)
ZA (1) ZA986364B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
ATE385421T1 (de) * 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2001062295A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicaments contenant des ingredients actifs combines
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
TWI339586B (en) 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー 3−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
BG104062A (en) 2000-11-30
TR200000133T2 (tr) 2000-09-21
DZ2563A1 (fr) 2003-02-15
GB9715298D0 (en) 1997-09-24
IL133907A0 (en) 2001-04-30
AR019724A2 (es) 2002-03-13
WO1999003478A1 (fr) 1999-01-28
KR20010021952A (ko) 2001-03-15
NO20000230D0 (no) 2000-01-17
EP1001784A1 (fr) 2000-05-24
NO20000230L (no) 2000-01-17
CN1263467A (zh) 2000-08-16
ID23804A (id) 2000-05-11
BR9810292A (pt) 2000-09-19
PE99499A1 (es) 1999-12-18
ZA986364B (en) 2000-01-17
HUP0003626A2 (hu) 2001-05-28
AU8449098A (en) 1999-02-10
SK612000A3 (en) 2000-07-11
OA11312A (en) 2003-10-24
CA2297133A1 (fr) 1999-01-28
PL338140A1 (en) 2000-09-25
UY25101A1 (es) 2000-12-29
MA24608A1 (fr) 1999-04-01
HUP0003626A3 (en) 2001-12-28
AR016350A1 (es) 2001-07-04
EA200000140A1 (ru) 2000-06-26
JP2001510160A (ja) 2001-07-31
CO4940489A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
CA2294582A1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de metformine
MY124695A (en) Novel composition and use.
AP2001002291A0 (en) Novel method of treatment.
TR199903095T2 (xx) Diabetin roziglitazon ve ins�lin ile tedavisi.
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
MY125855A (en) Treatment of diabetes with a thiazolidinedione and sulphonylurea
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
NO20000230L (no) Behandling av diabetes med tiazolidindion, insulin sekretagogue og <alfa>glukosidaseinhibitor
HK1041201A1 (zh) 貝塔激動劑和抗糖尿病製劑的配伍
WO2001047509A3 (fr) Procede de traitement
ECSP982592A (es) Nuevo metodo de tratamiento v
ECSP982591A (es) Nuevo metodo de tratamiento iv
AP2000001787A0 (en) Use of thiazolidinediones for the treatment of hyperglycaemia.
ECSP982542A (es) Nuevo metodo de tratamiento iii
HUP0002668A2 (hu) Diabetes kezelésére dioxo-tiazolidinnel és metforminnal
ECSP982534A (es) Nuevo metodo de tratamiento
ECSP982593A (es) Nuevo metodo de tratamiento vi
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982535A (es) Nuevo metodo de tratamiento (i)
HK1028551A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor